Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune